One-Year Results of GENOSS PCB Real-World Study in Femoropopliteal Artery Disease

NCT07431437 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-02-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of GENOSS PCB by enrolling and tracking patients who underwent percutaneous transluminal angioplasty using GENOSS PCB in patients with femoropopliteal artery disease.

Conditions

  • PTA (Percutaneous Transluminal Angioplasty)
  • Femoropopliteal Artery Disease

Sponsors & Collaborators

  • Genoss Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-17
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07431437 on ClinicalTrials.gov